v3.26.1
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance at Dec. 31, 2024 $ (97,283) $ 1 $ 1,957,261 $ 8 $ (2,054,553)
Beginning balance (in shares) at Dec. 31, 2024   5,859      
RSU settlements, net of shares withheld, shares   65      
Stock-based compensation expense 4,209   4,209    
Net (loss) income 38,010       38,010
Unrealized gain (loss) on available-for-sale securities (8)     (8)  
Ending balance at Mar. 31, 2025 (55,072) $ 1 1,961,470 0 (2,016,543)
Ending balance (in shares) at Mar. 31, 2025   5,924      
Beginning balance at Dec. 31, 2024 (97,283) $ 1 1,957,261 8 (2,054,553)
Beginning balance (in shares) at Dec. 31, 2024   5,859      
Issuance of pre-funded warrants in connection with HCRx Amendment 0        
Net (loss) income 40,397        
Unrealized gain (loss) on available-for-sale securities (8)        
Ending balance at Jun. 30, 2025 (35,041) $ 1 1,979,114 0 (2,014,156)
Ending balance (in shares) at Jun. 30, 2025   6,978      
Beginning balance at Mar. 31, 2025 (55,072) $ 1 1,961,470 0 (2,016,543)
Beginning balance (in shares) at Mar. 31, 2025   5,924      
RSU settlements, net of shares withheld (1)   (1)    
RSU settlements, net of shares withheld, shares   220      
Issuance of pre-funded warrants to purchase common stock through an underwritten registered direct offering 14,843   14,843    
Issuance of pre-funded warrants to purchase common stock through an underwritten registered direct offering, Shares   834      
Issuance of common stock pursuant to employee stock awards 1   1    
Stock-based compensation expense 2,801   2,801    
Net (loss) income 2,387       2,387
Unrealized gain (loss) on available-for-sale securities 0        
Ending balance at Jun. 30, 2025 (35,041) $ 1 1,979,114 0 (2,014,156)
Ending balance (in shares) at Jun. 30, 2025   6,978      
Beginning balance at Dec. 31, 2025 (38,502) $ 1 1,983,361 1 (2,021,865)
Beginning balance (in shares) at Dec. 31, 2025   7,324      
Issuance of pre-funded warrants in connection with HCRx Amendment 1,672   1,672    
Issuance of common stock through ATM facilities, net of commissions and offering costs, value 2,915   2,915    
Issuance of common stock through ATM facilities, net of commissions and offering costs, shares   493      
Exercise of pre-funded warrants, Share   630      
RSU settlements, net of shares withheld, shares   65      
Stock-based compensation expense 749   749    
Net (loss) income (4,145)       (4,145)
Unrealized gain (loss) on available-for-sale securities (1)     (1)  
Ending balance at Mar. 31, 2026 (37,312) $ 1 1,988,697 0 (2,026,010)
Ending balance (in shares) at Mar. 31, 2026   8,512      
Beginning balance at Dec. 31, 2025 (38,502) $ 1 1,983,361 1 (2,021,865)
Beginning balance (in shares) at Dec. 31, 2025   7,324      
Issuance of pre-funded warrants in connection with HCRx Amendment 1,672        
Net (loss) income (8,979)        
Unrealized gain (loss) on available-for-sale securities (3)        
Ending balance at Jun. 30, 2026 (36,996) $ 1 1,993,849 (2) (2,030,844)
Ending balance (in shares) at Jun. 30, 2026   9,443      
Beginning balance at Mar. 31, 2026 (37,312) $ 1 1,988,697 0 (2,026,010)
Beginning balance (in shares) at Mar. 31, 2026   8,512      
Issuance of common stock through ATM facilities, net of commissions and offering costs, value 4,758   4,758    
Issuance of common stock through ATM facilities, net of commissions and offering costs, shares   498      
Exercise of pre-funded warrants, Share   362      
RSU settlements, net of shares withheld, shares   71      
Stock-based compensation expense 394   394    
Net (loss) income (4,834)       (4,834)
Unrealized gain (loss) on available-for-sale securities (2)     (2)  
Ending balance at Jun. 30, 2026 $ (36,996) $ 1 $ 1,993,849 $ (2) $ (2,030,844)
Ending balance (in shares) at Jun. 30, 2026   9,443